Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q2 FY26 results · Jul–Sep 2025
Glenmark Pharmaceuticals reported revenue from operations of ₹6,046.87 crore (up 76.1% from Q2 FY25) and net profit of ₹610.43 crore (up 72.2% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 6,046.87 | 3,433.80 | +76.1% | 3,264.44 | +85.2% |
| Other income | 200.63 | 39.42 | +409.0% | 26.44 | +658.8% |
| Total income | 6,247.50 | 3,473.21 | +79.9% | 3,290.88 | +89.8% |
| Profit before tax | 967.40 | 472.57 | +104.7% | 95.58 | +912.2% |
| Net profit for the period | 610.43 | 354.49 | +72.2% | 46.97 | 13x |
| Attributable to shareholders of the company | 610.35 | — | — | 46.87 | 13x |
| EPS, basic (₹) | 21.63 | 12.55 | +72.4% | 1.66 | 13x |
| Net margin (%) | 10.1 | 10.3 | 1.4 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,538.66 | 2,636.10 | −41.6% | 2,394.93 | −35.8% |
| Other income | 285.76 | 83.08 | +244.0% | 69.33 | +312.1% |
| Total income | 1,824.42 | 2,719.18 | −32.9% | 2,464.26 | −26.0% |
| Profit before tax | (906.37) | 795.06 | Turned loss | 401.17 | Turned loss |
| Net profit for the period | (739.19) | 595.06 | Turned loss | 330.23 | Turned loss |
| EPS, basic (₹) | (26.19) | 21.09 | Turned loss | 11.70 | Turned loss |
| Net margin (%) | -48.0 | 22.6 | 13.8 |
Consolidated
- Filed with BSE
- 14 Nov 2025, 20:50 IST
- Board meeting
- 14 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Nov 2025, 20:50 IST
- Board meeting
- 14 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE